ストックスクリーナーアプリを入手
3.36
88.71%
-26.39
前日終値:
$29.75
開ける：
$3.72
24時間の取引高:
435.85K
Relative Volume:
36.04
時価総額：
$2.25M
収益：
$1.99M
当期純損益:
$-5.28M
株価収益率:
-2.4477
EPS:
-1.3727
ネットキャッシュフロー:
$-3.59M
1週間 パフォーマンス:
-89.38%
1か月 パフォーマンス:
-86.55%
6か月 パフォーマンス:
-67.79%
1年 パフォーマンス:
-81.54%
1日の値動き範囲:
$2.82
$3.84
1週間の範囲:
$2.82
$36.33
52週間の値動き範囲:
$2.82
$59.36
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
名前
Cyclerion Therapeutics Inc
セクター
電話
617-621-7722
住所
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.36 | 2.25M | 1.99M | -5.28M | -3.59M | -1.3727 |
VRTX
Vertex Pharmaceuticals Inc
|
522.51 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.25 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.41 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.74 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.19 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-20 | 開始されました | Truist | Buy |
| 2021-09-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 開始されました | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc (CYCN) 最新ニュース
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million - The Manila Times
Korsana Biosciences Completes Closing of Merger with - GlobeNewswire
Cyclerion Therapeuticsinc Stock Price Forecast. Should You Buy CYCN? - StockInvest.us
Cyclerion Therapeutics Inc. (CYCN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cyclerion Therapeutics Inc. (CYCN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cyclerion Shareholders Approve Key Measures for Korsana Merger - TipRanks
Cyclerion TherapeuticsSets Sept 4, 2026 As Record Date For Cvr Distribution In Korsana MergerSEC Filing - TradingView
Balyasny Asset Management L.P. Initiates Position in Cyclerion T - GuruFocus
Cyclerion (NASDAQ: CYCN) CFO buys 25,000 shares in cash exercise - Stock Titan
Cyclerion (CYCN) CEO uses cashless exercise, forfeits 48,629 options - Stock Titan
Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership - Stock Titan
Cyclerion Therapeutics (CYCN): Balyasny group discloses 7.33% equity position - Stock Titan
Cyclerion (NASDAQ: CYCN) details Korsana merger plans and proxy materials - Stock Titan
Cyclerion Therapeutics (CYCN) outlines two-step merger structure with Korsana Biosciences - Stock Titan
Cyclerion Therapeutics (CYCN) outlines terms, risks and disclosures for proposed Korsana merger - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cyclerion FY26 Q2 net loss widens to $1.76 million; revenue falls to no revenue - Bitget
Cyclerion Therapeutics 2Q 2026: Revenue $0 Net loss $(1.76M) — 10-Q Summary - TradingView
Cyclerion Therapeutics (NASDAQ: CYCN) outlines Korsana merger and going concern risk - stocktitan.net
Cyclerion (CYCN) and Korsana add leaders as reverse merger targets Q3 2026 close - Stock Titan
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Cyclerion Therapeutics (CYCN) Holds Flat at $3.49 as Shares Trade Within Established RangeMid Cap Momentum - dars.gov.et
Cyclerion Therapeutics (CYCN) Slides to $3.44 as Clinical-Stage Biotech Holds Key Support ZoneGap Down Bounce Plays - vinanet.vn
Cyclerion Therapeutics (CYCN) Slips 1.7% to $3.44 as Consolidation ContinuesCall Flow Alert - vinanet.vn
CYCN Q4 2025 Earnings: Narrower-Than-Expected Loss Beats Estimates as Cost Discipline Takes Center Stage - vinanet.vn
Cyclerion Therapeutics (CYCN) Stock Slides Slightly as It Tests Key Support LevelTWAP Entry - vinanet.vn
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics (CYCN) Slides 3.31% as Stock Tests Key Support LevelsRVOL Breakout - po-news-eg.net
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics Inc (CYCN) Balance Sheet - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.370|Chg%:-0.130 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.440|Chg%:-0.060 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RKLBRocket Lab Stock Price Today, News, Analysis and Trading Ideas - Stocktwits
Cyclerion Therapeutics (CYCN) plans merger with Korsana and $380M financing - Stock Titan
Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com South Africa
Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion - Stock Titan
Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares - Stock Titan
Cyclerion Therapeutics Q4 2025 Earnings: Narrowing Losses Beat Expectations Amid Strategic Pipeline FocusFinancial Data - vinanet.vn
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Tightens Cost ControlProfit Recovery Report - dars.gov.et
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beat Driven by Disciplined Cost Management, Stock DeclinesManagement Tone Analysis - vinanet.vn
Cyclerion Therapeutics (CYCN) Retreats 1.9% as Stock Tests Crucial Support ZoneHidden Order - dars.gov.et
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal - Stock Titan
Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing - Stock Titan
Cyclerion Therapeutics (CYCN) Presses Lower: Support Test in FocusETF Creation Redemption - dars.gov.et
Cyclerion Therapeutics Inc (CYCN) 財務データ
収益
当期純利益
現金流量
EPS
1.30%
0.62%
大文字化:
|
ボリューム (24 時間):